Skip to main content
SpringerLink
Log in

Lubiprostone

RU 0211, SPI 0211

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Takeda Pharmaceutical Company Limited, Sucampo Pharmaceuticals Inc. Sucampo and Takeda to Enter into an Agreement for a New Drug, Lubiprostone, for Chronic Constipation and Constipation-predominant Irritable Bowel Syndrome. Media Release: 1 Nov 2004. Available from URL: http://www.takeda.co.jp

    Google Scholar 

  2. Sucampo Pharmaceuticals Inc. Sucampo Receives $20 Million From Takeda for Development Milestone. Media Release 16 May 2005. Available from URL: http://www.sucampo.com

    Google Scholar 

  3. Sucampo Pharmaceuticals Inc. Sucampo Submits New Drug Application for Lubiprostone, an Investigational Compound for the Treatment of Chronic Idiopathic Constipation. Media Release: 1 Apr 2005. Available from URL: http://www.sucampo.com

    Google Scholar 

  4. Johanson JF, Gargano MA, Patchen ML, et al. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation. Gastroenterology 122 (Suppl. 1): 315, Apr 2002

    Google Scholar 

  5. Johanson JF, Gargano MA, Holland PC, et al. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology 124 (Suppl. 1): 48, Apr 2003

    Article  Google Scholar 

  6. Sucampo Pharmaceuticals Inc. Second Sucampo Phase III Safety Study Confirms First Study’s Significant Results for Constipation Treatment With SPI-0211. Media Release: 18 Feb 2004. Available from URL: http://www.sucampo.com

    Google Scholar 

  7. Cuppoletti J, Malinowska DH, Tewari KP, et al. Recombinant and native intestinal cell CIC-2 CI channels are activated by RU-0211. Gastroenterology 122 (Suppl. 1): 538, Apr 2002

    Google Scholar 

  8. Sucampo Pharmaceuticals Inc. Active Treatment Period of Sucampo’s Randomized Withdrawal Study Mirrors Positive Results of Previous Pivotal Efficacy Studies for Constipation Treatment With SPI-0211. Media Release: 11 May 2004. Available from URL: http://www.sucampo.com

    Google Scholar 

  9. Johnson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology 126 (Suppl. 2): 100, No. 4, Apr 2004

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lubiprostone. Drugs R D 6, 245–248 (2005). https://doi.org/10.2165/00126839-200506040-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200506040-00009

Keywords

Search

Navigation